The estimated Net Worth of Melissa Kelly Behrs is at least $1.92 Million dollars as of 29 May 2015. Ms. Behrs owns over 2,380 units of Geron stock worth over $529,588 and over the last 21 years she sold GERN stock worth over $489,911. In addition, she makes $898,657 as Executive Vice President and Chief Business Officer at Geron.
Melissa has made over 9 trades of the Geron stock since 2011, according to the Form 4 filled with the SEC. Most recently she sold 120,635 units of GERN stock worth $241,270 on 9 April 2019.
The largest trade she's ever made was selling 120,635 units of Geron stock on 9 April 2019 worth over $241,270. On average, Melissa trades about 4,954 units every 65 days since 2003. As of 29 May 2015 she still owns at least 120,635 units of Geron stock.
You can see the complete history of Ms. Behrs stock trades at the bottom of the page.
Melissa A. Kelly Behrs serves as Executive Vice President, Chief Business Officer of the Company. Previously, she was our Executive Vice President, Business Development and Portfolio & Alliance Management, from February 2014 to January 2019, and our Senior Vice President, Portfolio and Alliance Management from September 2012 to February 2014. Ms. Behrs joined Geron in November 1998 as Director of Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998, Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.
As the Executive Vice President and Chief Business Officer of Geron, the total compensation of Melissa Behrs at Geron is $898,657. There are 6 executives at Geron getting paid more, with John Scarlett having the highest compensation of $1,941,140.
Melissa Behrs is 56, she's been the Executive Vice President and Chief Business Officer of Geron since 2019. There are 11 older and 9 younger executives at Geron. The oldest executive at Geron Corp. is Stephen N. Rosenfield, 71, who is the Exec. VP, Chief Legal Officer & Corp. Sec..
Melissa's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury, and Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Geron executives and other stock owners filed with the SEC include: